Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AbbVie is conducting a Phase 2, multicenter study to evaluate targeted therapies for treating moderately to severely active Rheumatoid Arthritis (RA). The study aims to assess the efficacy and safety of these therapies, which include lutikizumab and ravagalimab, either as monotherapies or in combination, compared to a placebo. Approximately 180 participants, who have not responded to one or two prior biologic or targeted synthetic disease-modifying antirheumatic drugs, will be enrolled across 65 global sites.
The interventions being tested are lutikizumab and ravagalimab, both administered via subcutaneous injection. These drugs are designed to target specific pathways involved in RA to reduce symptoms and improve joint function.
The study follows a randomized, parallel assignment model with double masking for both participants and investigators to ensure unbiased results. The primary purpose is treatment-focused, aiming to find effective therapies for RA.
The study began on June 20, 2025, with the latest update submitted on June 30, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
This study could significantly impact AbbVie’s stock performance by potentially expanding its RA treatment portfolio. Positive results may enhance investor confidence, especially in a competitive market where effective RA treatments are in high demand.
The study is ongoing, and further details can be found on the ClinicalTrials portal.